Esperion Therapeutics (ESPR)

Esperion’s core products are based on bempedoic acid, an oral, once-daily, non-statin medicine designed to lower LDL-C. Its portfolio includes a bempedoic acid tablet and a fixed-dose combination tablet that pairs bempedoic acid with ezetimibe, another cholesterol-lowering agent. These medicines are intended for patients who need additional LDL-C reduction, including people who cannot reach treatment goals with existing therapies or who have difficulty tolerating statins.

The company’s strategy is closely tied to the commercial performance, clinical positioning, and market access of these two products. That creates a concentrated business model, with revenue prospects depending heavily on prescription growth, reimbursement coverage, physician adoption, and the competitive landscape in cardiovascular care. Esperion also manages partnerships and commercialization arrangements outside the United States, reflecting the global nature of cholesterol treatment markets.

As a listed healthcare stock, Esperion offers exposure to the cardiovascular therapeutics sector, where demand is driven by the large prevalence of high cholesterol and heart disease risk. Its distinctive feature is its emphasis on oral non-statin LDL-C reduction rather than injectable biologics or broad primary-care drug portfolios.